R. Jude Samulski Awarded Inaugural Founders Award from Chinese Society of Gene & Cell Therapy

Introduction

R. Jude Samulski, Ph.D., a prominent figure in the field of gene therapy, recently received the inaugural Founders Award from the Chinese Society of Gene & Cell Therapy (CSGCT). This prestigious accolade sets a remarkable precedent as Samulski becomes the first scientist to attain Founders Awards from leading gene therapy organizations across Asia, Europe, and North America.

A Historic Achievement

On October 2, 2026, M34 Inc. proudly announced that Dr. Samulski was honored at the CSGCT’s 2026 Annual Meeting held in Beijing from September 19 to 20. Recognizing individuals whose scientific leadership and innovations contribute significantly to the advancement of gene therapy, the Founders Award, presented for the first time this year, underlines Samulski's impactful contributions to the field.

Prior to this honor, Dr. Samulski received similar accolades from the European Society of Gene and Cell Therapy in 2022 and the American Society of Gene and Cell Therapy in 2026, highlighting his significant influence and leadership in the global gene therapy community.

A Legacy in Gene Therapy

Dr. Samulski’s groundbreaking work as one of the pioneers of modern gene therapy has led to significant advancements within the field. He was instrumental in cloning the adeno-associated virus (AAV) for therapeutic purposes—an achievement that has established AAV as a crucial delivery platform for genetic treatments. This technology underpins several FDA-approved therapies, including Zolgensma, which addresses spinal muscular atrophy (SMA), a severe genetic neuromuscular disorder.

Over his extensive career spanning more than four decades, Samulski has authored upwards of 250 scientific publications and holds more than 350 patents. As the founder of the University of North Carolina Gene Therapy Center and past president of the American Society of Gene and Cell Therapy, his leadership is integral to the continued evolution of gene therapy. He also co-founded Asklepios BioPharmaceutical (AskBio), which was later acquired by Bayer in a substantial deal valued up to $4 billion.

Addressing Global Collaboration

During his acceptance speech, Dr. Samulski expressed profound gratitude for receiving such recognition from his peers in China. He emphasized that scientific progress hinges on collaboration transcending geographical boundaries. He stated, "Science moves forward through collaboration across borders, and continued cooperation among researchers in the United States, China, and around the world will be essential to turning promising discoveries into meaningful treatments for patients."

Future Endeavors

At M34 Inc., Dr. Samulski is actively engaged in exploring innovative therapeutic strategies, especially for neurodegenerative diseases. The company, established in 2021 and based in Chapel Hill, North Carolina, aims to create breakthrough therapies by advancing in vivo and in situ cellular transdifferentiation methods and designing recombinant AAV vectors tailored for human applications. These efforts aspire to enhance the safety, effectiveness, and accessibility of gene therapies specifically targeting brain and spinal cord diseases.

Conclusion

The Founders Award from CSGCT marks a significant milestone in Dr. Samulski's illustrious career, reflecting not only his individual contributions but also the value of global partnerships in the advancement of gene therapy. As the field continues to evolve, Samulski's pioneering work promises to lead to exciting developments that could offer hope and healing for countless individuals suffering from genetic disorders.

With the support of organizations like the Columbus Children's Foundation, which prioritizes the development of gene therapies for ultra-rare pediatric diseases, the pathway to revolutionary treatments is becoming clearer every day. Through collaboration, diligence, and innovation, the future of gene therapy looks brighter than ever.